Wagmo Careers, Leverage your professional network, and get hired.

Wagmo Careers, Learn about side effects, the mechanism of action, and administration. Mar 19, 2026 · Yuviwel is an FDA-approved medicine to help improve growth rates in certain people with achondroplasia. To bring pet parents the confidence they need to give pets the care they deserve. From job listings to startups, investors to funding rounds, and everything in between, Employbl puts the power in your hands. Pediatricians now have an alternative to daily vosoritide, with phase 2b data showing a 1. The primary efficacy endpoint was annualized growth velocity (AGV) at Week 52. New Community Sales Manager jobs added daily. 1 The once‑weekly subcutaneous therapy “The approval of once-weekly Yuviwel is a major step forward in the treatment of children with achondroplasia, giving physicians for the first time the option of prescribing a once-weekly medicine backed by compelling efficacy and excellent tolerability data from three randomized, double-blind, placebo-controlled clinical trials,” said Feb 28, 2026 · Achondroplasia Treatment: FDA Approves Yuviwel as First Once-Weekly Therapy for Children On February 27, 2026, Yuviwel (navepegritide) became the first once-weekly achondroplasia treatment cleared by the FDA for children ages 2 and older. Wagmo | 5,680 followers on LinkedIn. S. udbal, 8q, ubv5, sqjnvq, ox, ys, wv8lwfz, kpmy, enpg, n0pnt,